Giving healthcare companies and their stories the exposure they deserve.





Maxim starts Monopar Therapeutics at buy; PT $11

Maxim Group launched coverage of Monopar Therapeutics (NASDAQ:MNPR) with a “buy” rating and a 12-month price target of $11. The stock closed at $4.98 on Sept. 24. Monopar is focused on developing therapies for cancer...

BTIG starts MediWound at buy; PT $6

BTIG initiated coverage of MediWound (NASDAQ:MDWD) with a “buy” rating and $6 price target. The stock closed at $3.58 on Sept. 22. MediWound has developed proteolytic enzyme technology targeting severe burns, chronic...

Precipio launches HemeScreen AML

Precipio (NASDAQ:PRPO) launched its HemeScreen acute myeloid leukemia (AML) panel, which tests for the presence of mutations in certain genes to help develop a treatment plan for patients. The company noted that AML...

HCW ups OSE Immunotherapeutics PT to €10 from €7

H.C. Wainwright raised its price target for OSE Immunotherapeutics (NXT PA:OSE) to €10 from €7, citing strong results in PD-1 refractory non-small cell lung cancer (NSCLC) from the first 100-patient cohort of the Phase...

WB starts Aravive at OP

William Blair launched coverage of Aravive (NASDAQ:ARAV) with an “outperform” rating, saying that an “appreciable market disconnect exists between lead asset AVB-500’s potential to emerge as a differentiated therapeutic...

FDA clears Acutus’ AcQMap catheter

The FDA cleared Acutus Medical’s (NASDAQ:AFIB) AcQMap, a 3D mapping and navigation catheter designed to be inserted into the left and right atrium. In addition to cardiac activation mapping, the AcQMap catheter can...

Just a few of the companies we’ve highlighted along the way


Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.